Zhengye Biotechnology Holding (ZYBT) Non-Current Assets (2023 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Non-Current Assets of $42.2 million for Q4 2025, down 4.06% year-over-year from $43.9 million in Q4 2024, and little changed quarter-over-quarter from $42.3 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Non-Current Assets (2023 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Non-Current Assets for 3 consecutive years, with $42.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 4.06% year-over-year to $42.2 million; the TTM figure through Dec 2025 stood at $42.2 million (down 4.06% YoY), while the FY2025 annual figure was $42.8 million, down 1.13% from the prior year.
- Non-Current Assets steadied at $42.2 million in Q4 2025 per ZYBT's latest filing, from $42.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $43.9 million in Q4 2024 and bottomed at $42.2 million in Q4 2025.
- Historically, Non-Current Assets has averaged $42.9 million across 3 years, with a median of $42.7 million in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Assets rose 1.86% — and 2025, when it declined 4.06%.
- Zhengye Biotechnology Holding's Non-Current Assets stood at $43.1 million in 2023, then grew by 1.86% to $43.9 million in 2024, then decreased by 4.06% to $42.2 million in 2025.
- Business Quant data shows ZYBT's Non-Current Assets at $42.2 million in Q4 2025, $42.3 million in Q2 2025, and $43.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Zhengye Biotechnology Holding | 88.82 Mn | 81.50 Mn | - | 42.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42.16 Mn |
| Jun 30, 2025 | 42.32 Mn |
| Dec 31, 2024 | 43.95 Mn |
| Dec 31, 2023 | 43.14 Mn |